HanahanD. Hallmarks of Cancer: New Dimensions. Cancer Discov. 12, 31–46 (2022).
2.
TissotT.et al.Metastasis and the evolution of dispersal. Proceedings. Biol. Sci., 286, 20192186 (2019).
3.
Eslami-SZ., Cortés-HernándezL. E., ThomasF., PantelK. & Alix-PanabièresC.Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. Br. J. Cancer (2022). doi:10.1038/s41416-022-01819-1
DongreA. & WeinbergR.A.. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol., 20, 69–84 (2019).
6.
JoosseS. A.et al.Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. Clin. Chem., 66, 161–168 (2020).
7.
FidlerI. J.The pathogenesis of cancer metastasis: the ‘seed and soil' hypothesis revisited. Nat. Rev. Cancer, 3, 453–458 (2003).
8.
FidlerI. J.Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J. Natl. Cancer Inst., 45, 773–782 (1970).
9.
DujonA. M.et al.Is There One Key Step in the Metastatic Cascade?. Cancers (Basel)., 13, (2021).
10.
CayrefourcqL.et al.Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones. Molecular cancer, 20, 30 (2021).
11.
Balcik-ErcinP., CayrefourcqL., SoundararajanR., ManiS. A. & Alix-PanabièresC.Epithelial-to-Mesenchymal Plasticity in Circulating Tumor Cell Lines Sequentially Derived from a Patient with Colorectal Cancer. Cancers, 13, (2021).
12.
YangJ.et al.Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol., 21, 341–352 (2020).
13.
AcetoN.Bring along your friends: Homotypic and heterotypic circulating tumor cell clustering to accelerate metastasis. Biomed. J., 43, 18–23 (2020).
14.
DonatoC.et al.Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells. Cell Rep., 32, 108105 (2020).
Eslami-SZ., Cortés-HernándezL. E. & Alix-PanabièresC.The Metastatic Cascade as the Basis for Liquid Biopsy Development. Front. Oncol., 10, 1055 (2020).
17.
ShibueT. & WeinbergR. A.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol., 14, 611–629 (2017).
18.
Cortés-HernándezL. E., Eslami-SZ., PantelK. & Alix-PanabièresC.Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. Clin. Chem., 66, 97–104 (2020).
19.
Eslami-SZ., Cortés-HernándezL. E. & Alix-PanabièresC.Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. Cells, 9, (2020).
20.
Alix-PanabièresC.et al.Detection of Circulating Prostate-Specific Antigen– Secreting Cells in Prostate Cancer Patients. Clin. Chem., 51, 1538 LP–1541 (2005).
21.
BidardF.-C.et al.Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. JAMA Oncol., 7, 34–41 (2021).
22.
JacotW.et al.Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Clin. Chem., 66, 1093–1101 (2020).
23.
MazelM.et al.Frequent expression of PD-L1 on circulating breast cancer cells. Mol. Oncol., 9, 1773–1782 (2015).
24.
ScherH. I.et al.Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol., 2, 1441–1449 (2016).
25.
Alix-PanabièresC. & PantelK.Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov., 11, 858–873 (2021).
26.
LiuM. C., OxnardG.R., KleinE. A., SwantonC. & SeidenM.V.. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 31, 745–759 (2020).
27.
MattoxA. K.et al.Applications of liquid biopsies for cancer. Sci. Transl. Med., 11, (2019).
